Breaking News

Teva To Acquire NuPathe

By Kristin Brooks | January 21, 2014

Expands CNS portfolio

Teva Pharmaceutical Industries Ltd. has entered into a definitive agreement to acquire NuPathe Inc. for approximately $144 million in cash. NuPathe shareholders may also receive additional payments if sales milestones are met for NuPathe’s migraine treatment, ZECUITY. The transaction is expected to close in February 2014.
Teva expands its central nervous system (CNS) portfolio with ZECUITY, the first prescription migraine patch approved by the FDA for the acute treatment of migraine in adults. ZECUITY is a disposable, single-use, iontophoretic transdermal patch that actively delivers sumatriptan, a widely prescribed migraine medication. Teva also gains access to NuPathe’s technology, including its transdermal delivery system.
“We believe that ZECUITY is a great fit within our existing U.S. CNS Business Unit, with near-term sales and significant commercial potential," said Mike Derkacz, vice president and general manager, Teva CNS. “ZECUITY enables rapid transdermal delivery of sumatriptan and bypasses the GI tract to avoid issues with oral intake, addressing an important, unmet patient need, especially for those with migraine-related nausea. At Teva, we will leverage our unique Shared Solutions infrastructure to support patient utilization of this important new medicine for migraine sufferers.”
Additionally, NuPathe has terminated its previous merger agreement with Endo, and as a result, Endo received a $5 million termination fee from NuPathe.   
"We believe that the agreement NuPathe has signed with Teva is positive news for NuPathe stockholders and as a result we accepted the termination fee and are now proceeding to withdraw our tender offer," said Rajiv De Silva, president and chief executive officer of Endo. "We believe our offer represented fair value for NuPathe. We will remain disciplined in our approach to M&A and will look to deploy capital on other opportunities to create value for our shareholders."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks